Gallant’s Stem Cell Breakthrough Signals a New Era in Veterinary MedicineIn early 2026, animal health biotechnology company Gallant announced a major milestone: its ready-to-use stem cell therapy Sonruvetcel for refractory feline chronic gingivostomatitis (FCGS) is approaching conditional approval by the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM).The therapy has already received “Technical Section Complete” letters for both Target Animal Safety and Reasonable Expectation of Effectiveness, key regulatory milestones required for conditional approval.If approved, Sonruvetcel could become the first FDA-approved, ready-to-use stem cell therapy in veterinary medicine,...